Skip to main
NBTX

Nanobiotix SA (NBTX) Stock Forecast & Price Target

Nanobiotix SA (NBTX) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 33%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Nanobiotix is a late-stage clinical biotechnology company with a positive outlook based on their innovative physics-based approach to developing nanotherapeutics for cancer treatment. The company has a strong portfolio of potential treatments, including their Nanoradioenhancer platform, Nanoprimer platform, and Neurological disease platform, with a focus on using nanoparticles to improve outcomes and minimize burden for patients. They have a partnership with JNJ and have promising preliminary data in various indications, with upcoming milestones and catalysts providing potential upside for investors.

Bears say

Nanobiotix is a clinical biotechnology company with unproven technology and a lack of current revenues or profitability. Its success hinges on the approval and uptake of its lead product candidate, JNJ-1900, and any delays or setbacks in clinical trials or regulatory approvals could negatively impact its financial stability. There are also concerns about the commercial viability of the company's novel approach and the potential for lower than expected sales post-approval. Overall, there are significant risks associated with investing in Nanobiotix, leading to a negative outlook on its stock.

Nanobiotix SA (NBTX) has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 33% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Nanobiotix SA and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Nanobiotix SA (NBTX) Forecast

Analysts have given Nanobiotix SA (NBTX) a Buy based on their latest research and market trends.

According to 3 analysts, Nanobiotix SA (NBTX) has a Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $46.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $46.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Nanobiotix SA (NBTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.